Regentis Biomaterials Ltd. announced the pricing of its initial public offering, with 1,250,000 shares at $8.00 each, raising $10,000,000. The Company’s ordinary shares will begin trading on the NYSE American LLC on December 4, 2025, under the symbol “RGNT”. Proceeds from the offering will fund development activities, including pivotal trials for GelrinC. ThinkEquity is the sole book-running manager for the Offering. GelrinC is Regentis’ lead product candidate, a cell-free hydrogel for treating articular knee cartilage injuries, with CE mark approval in Europe. For more information, visit https://www.regentis.co.il/.

This press release contains forward-looking statements regarding the Offering and use of proceeds. Regentis Biomaterials Ltd. is a regenerative medicine company focused on orthopedic treatments using its Gelrin platform. The Company’s efforts are dedicated to restoring health and enhancing patient quality of life. Forward-looking statements are based on current expectations and subject to inherent uncertainties and risks. For more detailed information on risks and uncertainties affecting Regentis, refer to the Company’s reports filed with the SEC. Contact Arie Gordashnikov for investor relations inquiries at [email protected] or +972-3-6116629.

Read more at GlobeNewswire: Regentis Biomaterials Ltd. Announces Pricing of Initial